Beam Therapeutics Q2 net loss $91.1M; cash $1.0B; BEAM-101 enrollment tops 20, six dosed

Beam Therapeutics Inc.

2024-Q2 EPS reported -$2.31 revenue$19,182,000

Net loss widened to $91.1M ($1.11/shr) from $82.8M ($1.08/shr) in Q2 2023.
Cash, cash equivalents and marketable securities $1.0B at June 30 vs $1.2B at Dec 31, 2023.
BEAM-101 Phase 1/2 BEACON trial: >20 patients enrolled, 6 dosed; initial data submitted for ASH.
FDA cleared IND for BEAM-301 (GSDIa); patient dosing expected in early 2025.
First patient dosed in BEAM-302 Phase 1/2 trial (AATD); initial clinical data expected in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.